Family Medicine
Analysis: How long does covid-19 immunity last?
1 Jul, 2021 | 09:56h | UTCHow long does covid-19 immunity last? – The BMJ
The neurological manifestations of post-acute sequelae of SARS-CoV-2 infection.
1 Jul, 2021 | 09:55h | UTC
Perspective | Why no one is sure if Delta is deadlier – “The variants are spreading faster, but they don’t necessarily have incentive to kill more often”.
1 Jul, 2021 | 09:52h | UTCWhy No One Is Sure If Delta Is Deadlier – The Atlantic
Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.
30 Jun, 2021 | 10:24h | UTC
Case Series: Myocarditis following immunization with mRNA COVID-19 vaccines.
30 Jun, 2021 | 10:22h | UTCSee also: Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination – JAMA Cardiology
Editorials: Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines AND Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working
Commentary: More Evidence Links Myocarditis to mRNA COVID-19 Vaccines – TCTMD
Commentary on Twitter
2 new reports of myocarditis after mRNA vaccination documenting its rare occurrence
23 males serving in the military among 2.8 million doses givenhttps://t.co/yPbYxkuSHi
4 cases in North Carolina, including a 70-year-old womanhttps://t.co/Iwj2Hx6O2U@JAMACardio pic.twitter.com/fv2JoOFAyt— Eric Topol (@EricTopol) June 29, 2021
Systematic Review: Cilostazol for intermittent claudication – “Cilostazol has been shown to improve walking distance in people with intermittent claudication. However, participants taking cilostazol had higher odds of experiencing headache”.
1 Jul, 2021 | 09:42h | UTCCilostazol for intermittent claudication – Cochrane Library
Summary: Cilostazol for peripheral arterial disease – Cochrane Library
Covid: Masks upgrade cuts infection risk, research finds.
30 Jun, 2021 | 10:16h | UTCCovid: Masks upgrade cuts infection risk, research finds – BBC
RCT: Among patients with diarrhea-predominant irritable bowel syndrome, a low FODMAP diet achieved earlier symptomatic improvements in stool frequency and excessive wind.
30 Jun, 2021 | 10:09h | UTC
Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.
30 Jun, 2021 | 10:11h | UTCRelated: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant – medRxiv
M-A: SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure.
30 Jun, 2021 | 10:08h | UTC
Review: Virtual consultation for red eye.
30 Jun, 2021 | 10:04h | UTCVirtual consultation for red eye – The BMJ
Commentary on Twitter
Red eye is a common ophthalmic presentation in primary care, accounting for 2 to 3% of the consultations.
How can you safely diagnose and manage patients with acute red eye(s) in a virtual consultation?https://t.co/cn12VYpyuW
— The BMJ (@bmj_latest) June 29, 2021
Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.
29 Jun, 2021 | 10:09h | UTCInvited commentary: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases
Commentary on Twitter
NEW—A phase 1/2 clinical trial of #CoronaVac in 550 children and adolescents aged 3-17 years in China suggests two doses of the vaccine are safe and generate a strong antibody response. Read in @TheLancetInfDis: https://t.co/eXSagRu1Cs pic.twitter.com/fOKNLUjNwc
— The Lancet (@TheLancet) June 28, 2021
SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses, suggesting immunity will be long-lasting.
29 Jun, 2021 | 10:03h | UTCSARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature
Commentaries: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical
Commentary on Twitter (thread – click for more)
Just published @nature
A bonus factor after covid vaccination: germinal center factories for durable, antigen-specific, B cells and plasmoblasts induced by mRNA vaccination, as determined by lymph node aspirates from vaccinees https://t.co/5eR0gDSWHq
@TheBcellArtist @WUSTLmed pic.twitter.com/C5xPSrh5Gw— Eric Topol (@EricTopol) June 28, 2021
[Preprint] 3rd AstraZeneca shot gives strong immunity.
29 Jun, 2021 | 10:01h | UTCStudy: 3rd AstraZeneca shot gives strong immunity – Reuters
Original Study (preprint): Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) – SSRN/The Lancet
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.
29 Jun, 2021 | 10:00h | UTC
Podcast | Evaluation and management of hypercalcemia.
29 Jun, 2021 | 09:51h | UTC#281 Hypercalcemia: Calci-fun! with Dr. Carl Pallais – The Curbsiders
Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.
28 Jun, 2021 | 10:01h | UTCCommentaries: Heterologous vaccine regimens against COVID-19 – The Lancet AND
Commentary on Twitter (thread – click for more)
NEW #COVID19 research—Phase 2 trial by @borobia_am, @antoniojcarcas
et al. reports BNT162b2 given as a 2nd dose in individuals prime vaccinated with ChAdOx1-S induced a robust immune response, with an acceptable and manageable reactogenicity profile. Read https://t.co/muL0XQxdjG. pic.twitter.com/BxPlXB8EF7— The Lancet (@TheLancet) June 26, 2021
WHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads.
28 Jun, 2021 | 09:55h | UTCWHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads – CNBC
Commentary on Twitter (thread – click for more)
⚠️WEAR MASK EVEN IF VACCINATED—Top @WHO leader urges masks against #DeltaVariant even if 2-dose vaxxed. "Vaccine alone won't stop community transmission. People need to use masks consistently, be in ventilated spaces—even if you're vaccinated" #COVID19🧵https://t.co/qPZTmcy9iW pic.twitter.com/j5V6fbHdoi
— Eric Feigl-Ding (@DrEricDing) June 26, 2021
Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.
28 Jun, 2021 | 09:52h | UTCIs one vaccine dose enough if you’ve had COVID? What the science says – Nature
Commentary on Twitter
One vaccine dose for prior covid: @ElieDolgin reviews the recent data @Nature https://t.co/amJ4RcGtuW
Vaccination cards/proof should be modified here to equate prior covid as the 1st dose and not force people to get an unnecessary 2nd dose— Eric Topol (@EricTopol) June 27, 2021
Study finds 96.1% of patients objectively recovered from anosmia 1 year after COVID-19 diagnosis.
28 Jun, 2021 | 09:49h | UTCClinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis – JAMA Network Open
Commentary: Did Covid-19 take your taste and smell? Here’s when they may return – CNN AND Lost Sense of Smell Returns for Almost All COVID Survivors – HealthDay
WHO: Delta variant is ‘most transmissible’ identified so far.
28 Jun, 2021 | 09:58h | UTCWHO: Delta variant is ‘most transmissible’ identified so far – Associated Press
Related: Delta COVID variant fuels global surges, complicates reopenings – CIDRAP AND Delta variant triggers dangerous new phase in the pandemic – Science AND Delta coronavirus variant: scientists brace for impact – Nature AND Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv AND COVID-19: The rise and rise of Delta – Sciblogs AND Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”.
Putting people first in managing their health: new WHO guideline on self-care interventions – “Whether it’s for their experience of pregnancy and childbirth; managing fertility intentions, preventing sexually transmitted infections; enjoying better sexual health of themselves or their partner, or self-monitoring their blood pressure, access to quality self-care interventions can help meet people’s many health needs and rights”.
28 Jun, 2021 | 09:40h | UTCNews release: Putting people first in managing their health: new WHO guideline on self-care interventions – World Health Organization
See guidance: WHO consolidated guideline on self-care interventions for health
Commentary on Twitter (thread – click for more)
https://twitter.com/WHO/status/1408350517428953091
RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.
28 Jun, 2021 | 09:46h | UTC
RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.
28 Jun, 2021 | 09:45h | UTCTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Combo GIP/GLP-1 Drug Superior for HbA1c Reduction in T2D – MedPage Today (free registration required)
[Preprint] Long Covid: Third of people infected have long term symptoms.
25 Jun, 2021 | 10:30h | UTCCovid-19: Third of people infected have long term symptoms – The BMJ
Original study (preprint): Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people – Imperial College London